On March 16, 2022, the first researcher meeting of Phase II of Lizaishi Injection was successfully held in Lize Business District, Fengtai, Beijing. Professor Zhang LAN of Capital Medical University Xuanwu Hospital, Professor Song Haiqing of Capital Medical University Xuanwu Hospital, Liu Chi, Deputy general manager of Fangwei Pharmaceutical (Rugao) Co., LTD., Deputy General manager of the Marketing Department, Kang Ting, director of CRO Fang Kuak Medical team and more than a dozen institutional teachers attended the meeting.

First of all, Professor Song Haiqing from Xuanwu Hospital, the group leader responsible for the project, delivered a speech. Professor Song said that the Phase II team is composed of many experienced institutions and is a strong team, and I believe that with the joint efforts and cooperation of the sponsor, CRO and institutions, the project will be successfully completed. Neuroprotective treatment of stroke has been the focus of attention in recent years, and it is hoped that more and more drugs with potential such as Lirex can be marketed to better improve the benefit space of patients. At the same time, Professor Song said that the Phase I project was launched in Xuanwu Hospital, which laid a good foundation. I believe that the Phase II project can also be successfully completed, and I look forward to fighting together with you!

Afterwards, Professor Zhang LAN introduced the Phase I experiment of the project, and expressed the expectation and confidence of the Phase II project. Professor Zhang said: The Phase I project evaluated the overall safety and tolerability of the drug, and the conclusions provided key data support for follow-up studies. As a Phase I team, it is gratifying and gratifying to see the clinical trials of Lirex making steady progress towards the ultimate goal of benefiting patients. Finally, Professor Zhang wishes and believes that the Phase II trial will be successfully completed under the leadership of Professor Song Haiqing!

At the meeting, Director Kang Ting of Wesh Pharmaceutical (Rugao) Co., Ltd. introduced the company and products in detail and put forward expectations, hoping that the team can complete the project with high quality under the premise of ensuring that the clinical trial data are true, accurate, complete, timely and legal. Subsequently, Dr. Wang Fang, Medical director of Quark Medicine, elaborated and trained on the test program, introduced the test purpose, the basic information of the project, the discharge standards and observation indicators, and especially emphasized the key points for attention in each link of the test. At the same time, an online discussion was initiated with various institutions to discuss the problems that may be encountered in the course of the experiment and answer questions.